期刊文献+

苦参碱聚乳酸微球玻璃体腔内注射的药代动力学研究 被引量:4

Study on pharmacokinetics of matrine polyactic acid microsphere after intravitreal injection
暂未订购
导出
摘要 目的研究苦参碱聚乳酸微球玻璃体腔注射后的药代动力学特点。方法将30只新西兰白兔随机分为10组,每组3只兔(6只眼)。除空白组外,其余各组每只眼玻璃体腔均注入苦参碱聚乳酸微球(含苦参碱4 mg)。分别在注药后10 min,2 h,1、3、7、14、21、28、35 d各处死1组动物取双侧眼球并制备玻璃体样本。应用高效液相色谱法检测玻璃体腔药物质量浓度,用DAS软件计算主要的药代动力学参数。结果玻璃体腔注入苦参碱聚乳酸微球(含苦参碱4 mg)后,药物在玻璃体内的平均滞留时间MRT=(221.64±9.70)h,半衰期t1/2=(173.77±32.33)h。缓释微球在玻璃体腔释药可达35 d以上,35 d时药物质量浓度为(121.8±34.6)μg/mL。随时间延长,药物的总体清除率稳定增加。结论玻璃体腔注入苦参碱聚乳酸微球(含苦参碱4 mg),药物在眼内清除较慢,清除时间明显延长,在玻璃体腔内能够长时间维持较高的质量浓度,表现出良好的体内缓释性。 Objective The inhibitor), effect of matrine polyactic acid microsphere (MAT-PLA-MS) on proliferative vitreoretinopathy(PVR) is associated with whether the injected drugs can maintain a high level in vitreous for longer-time duration. In order to determine the level of drug in vitreous, the pharmacokinetics of MAT-PLA-MS was examined in this study after intravitreal injection in rabbits. Methods Thirty healthy and mature New Zealand albino rabbits were randomly divided into 10 groups and 6 eyes of 3 rabbits for each. Rabbits in experimental groups received intravitreal implantation of MAT-PLA-MS (including matrine 4 rag) ,but drug did not be administrated in 3 animals of blank control group. At the 10th minutes,2nd hour, 1 st, 3 rd, 7th, 14th,21 st, 28th and 35 th day following injection, both eyes of animals in each group were removed respectively, and the vitreous specimens were obtained immediately for preparation and detection of matrine concentration by high performance liquid chromatography (HPLC). The main parameters of pharmacokinetics were calculated through DAS pharmacokinetics software. Results After intravitreal implantation of MAT-PLA-MS,the pharmacokinetics parameters of drug were as follows: MRT = 221. 64 ±9. 70 hours,t1/2 = 173.77±32.33 hours. At 10 minutes,2 hours,1 day,3,7,14,21,28 and 35 days after intravitreal implantation of MAT-PLA-MS, the mass concentration of matrine in vitreous was (3 086.2±164.1 ), (2 964.9 ± 223.4),(2791.6 ±224.2),(2303.3 ±181.5),(1 648.4±234.2),(882. 1±155.7),(484.3 ±81.2),(242.9±39.8), ( 121.8 ±34.6 ) μg/mL respectively, and the total clearance rate of matrine was 8.96 % , 12.53 % , 17.65 % , 32.05 % , 51.31% , 73.98% ,85.71% ,92.63% and 96.41% respectively. Conclusion Microsphere-encapsulated matrine has a long half life and mean remaining period. MAT-PLA-MS can maintain an effective drug concentration and shows controlled release characteristics.
出处 《眼科研究》 CSCD 北大核心 2009年第10期833-837,共5页 Chinese Ophthalmic Research
基金 河北省自然科学基金资助(303638)
关键词 苦参碱 聚乳酸 微球 玻璃体 高效液相色谱法 药代动力学 matrine polyactic acid microsphere vitreous high performance liquid chromatography pharmacokinetics
  • 相关文献

参考文献6

二级参考文献26

  • 1季宇彬.中药有效成分药理与应用[M].哈尔滨:黑龙江科学技术出版社,1994.294.
  • 2杨彬 宋俊生 等.双氯灭痛滴眼液对家兔实验性眼炎的治疗作用[J].现代应用药学,1993,10(2):5-5.
  • 3Nath KA. The tubulointerstitium in progressive renal disease. Kidney Int, 1998;54(3): 992.
  • 4Ishidoya S, Morrissey J. Angiotensin Ⅱ receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int,1995;47(5):1285.
  • 5Zhang Jun-Ping, Zhang Min. Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats. Acta Pharmacol Sin,2001;22(2):183.
  • 6Hu ZL, Zhang JP. Effects of matrine on mouse splenocyte proliferation and release of interleukin-1 and -6 from peritoneal macrophages in vitro. Acta Pharmacol Sin,1996;17(3):259.
  • 7Zhang Jun-Ping, Zhang Min. Matrine inhibits production and actions of fibrogenic cytokines released by mouse peritoneal macrophages. Acta Pharmacol Sin,2001;22(8):765.
  • 8Zhang Jun-Ping, Zhang Min. Matrine inhibits production and actions of fibrogenic cytokines released by mouse peritoneal macrophages. Acta Phammacol Sin,2001;22(8):765.
  • 9Heungsoo K, Takashi O. TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol,2001;12(4):736.
  • 10Liu Yun-Hai, Liu Yu-Fen. Current studies on anti-endotoxic chemical components of traditional Chinese medicine in china. Acta Pharmacol Sin, 2001;22(12):1071.

共引文献68

同被引文献85

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部